Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Idexx Laboratories (NASDAQ: IDXX), Zai Lab Ltd (NASDAQ: ZLAB) and Eli Lilly & Co (NYSE: LLY).
Idexx Laboratories (NASDAQ: IDXX)
In a report released today, Erin Wright from Credit Suisse maintained a Buy rating on Idexx Laboratories (NASDAQ: IDXX), with a price target of $231. The company’s shares closed yesterday at $224.98, close to its 52-week high of $229.01.
According to TipRanks.com, Wright is a 4-star analyst with an average return of 11.3% and a 69.2% success rate. Wright covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Diplomat Pharmacy, and Syneos Health Inc.
Idexx Laboratories has an analyst consensus of Strong Buy, with a price target consensus of $227.
See today’s analyst top recommended stocks >>
Zai Lab Ltd (NASDAQ: ZLAB)
In a report released today, John Sullivan from Leerink Partners maintained a Buy rating on Zai Lab Ltd (NASDAQ: ZLAB), with a price target of $43. The company’s shares closed yesterday at $24.18.
Zai Lab Ltd has an analyst consensus of Hold.
Eli Lilly & Co (NYSE: LLY)
Credit Suisse analyst Vamil Divan maintained a Sell rating on Eli Lilly & Co (NYSE: LLY) today and set a price target of $84. The company’s shares closed yesterday at $86.28.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.2% and a 46.2% success rate. Divan covers the Healthcare sector, focusing on stocks such as Aimmune Therapeutics, Johnson & Johnson, and Bristol Myers.
Eli Lilly & Co has an analyst consensus of Moderate Buy, with a price target consensus of $93.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
